We have spoken to Roche, Novartis Gene Therapies and Biogen about the continued supply of treatments for Spinal Muscular Atrophy. All three companies have clearly indicated that over the past 2 years they were preparing for various outcomes of Brexit negotiations, including a no deal option. As a result of those preparations there is now a suitable reserve of stock for the treatments and no disruption is foreseen.

We were reassured that the companies will continue to monitor the situation and ensure that patients’ needs are addressed